Gastric dumping syndrome medical therapy: Difference between revisions
Created page with "__NOTOC__ {{Gastric dumping syndrome}} Please help WikiDoc by adding content here. It's easy! Click here to learn about editing. {{CMG}} ==O..." |
|||
(66 intermediate revisions by 3 users not shown) | |||
Line 1: | Line 1: | ||
__NOTOC__ | __NOTOC__ | ||
{{Gastric dumping syndrome}} | {{Gastric dumping syndrome}} | ||
{{CMG}}; {{AE}} {{UA}} | |||
==Overview== | |||
The main [[therapy]] for the management of [[Gastric dumping syndrome|dumping syndrome]] includes [[Diet (nutrition)|diet]] and [[Pharmacology|pharmacological]] intervention. | |||
==Approach to Management== | |||
The following algorithm demonstrates the course of action in the approach of the management of dumping syndrome: | |||
<br><br> | |||
{{Familytree/start}} | |||
{{Familytree | | | | | | | | | | | | | | | | B01 | | | |B01='''Gastric or Esophageal Surgery''' }} | |||
{{Familytree | | | | | | | | | | | | | | | | |!| | | | | }} | |||
{{Familytree | | | | | |F|~|~|~|~|~| | |,|-|-|^|-|-|.| | }} | |||
{{Familytree | | | | | |:| | | | | | | A01 | | | | A02 | | |A01='''Early dumping symptoms'''|A02='''Late dumping symptoms'''}} | |||
{{Familytree | | | | | | | | | | | | | |`|-|-|v|-|-|'| | }} | |||
{{Familytree | | | | | B01 | | | | | | | | | B02 | | | |B01= Diagnosis| B02='''Measure Glucose'''}} | |||
{{Familytree | | | | | | | | | | | | | | | | |!| | | | | }} | |||
{{Familytree | | | | | |:| | | | | | | | | | B02 | | | |B02='''Confirm diagnosis with OGTT'''}} | |||
{{Familytree | | | | | |L|~|~|~|~|~|~|~|~| | |!| | | | | }} | |||
{{Familytree | | | | | |F|~|~|~|~|~| | |,|-|-|^|-|-|.| | }} | |||
{{Familytree | | | | | |:| | | | | | | A01 | | | | A02 | | |A01='''Dietary modifications'''|A02='''Dietary supplements'''}} | |||
{{Familytree | | | | | |:| | | | | | | |`|-|-|v|-|-|'| | }} | |||
{{Familytree | | | | | |:| | | | | | | | | | B04 | | | |C01=Treatment |B04='''Acarbose''' }} | |||
{{Familytree | | | | | | | | | | | | | | | | |!| | | | | }} | |||
{{Familytree | | | | | B01 | | | | | | | | | B02 | | | |B01=Treatment |B02='''Somatostatin analogues'''}} | |||
{{Familytree | | | | | | | | | | | | | | | | |!| | | | | }} | |||
{{Familytree | | | | | |:| | | | | | | | | | B05 | | | |B05= '''Treatment refractory dumping syndrome'''}} | |||
{{Familytree | | | | | |:| | | | | | | | | | |!| | | | | }} | |||
{{Familytree | | | | | |L|~|~|~|~|~|~|~|~| | B06 | | | |B06= '''Surgical re-intervention or Continuous enteral feeding'''}} | |||
{{Familytree/end}} | |||
<br> | |||
==Medical Therapy== | |||
Medical [[therapy]] for [[Gastric dumping syndrome|dumping syndrome]] includes [[Diet (nutrition)|diet]] and [[Medication|drug therapy]].<ref name="pmid16207692">{{cite journal |vauthors=Ukleja A |title=Dumping syndrome: pathophysiology and treatment |journal=Nutr Clin Pract |volume=20 |issue=5 |pages=517–25 |year=2005 |pmid=16207692 |doi=10.1177/0115426505020005517 |url=}}</ref><br> | |||
{| class="wikitable" | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Level of evidence | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Type of evidence | |||
|- | |||
|I | |||
|Evidence from [[meta-analysis]] of multiple, well-designed, controlled studies (randomized trials with low false-positive and low false-negative errors) | |||
|- | |||
|II | |||
|Evidence from at least 1 well-designed, quasi-experimental study (randomized trials with high false-positive and high false-negative errors) | |||
|- | |||
|III | |||
|Evidence from well-designed, quasi-experimental studies (nonrandomized, controlled, single-group, pre–post, [[Cohort study|cohort]] and time or matched [[Case–control study|case–control]] series) | |||
|- | |||
|IV | |||
|Evidence from well-designed, non-experimental studies (comparative and correlational descriptive and case studies) | |||
|- | |||
|V | |||
|Evidence from case reports | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Grade of recommendation | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Level of evidence | |||
|- | |||
|A | |||
|Level I evidence or consistent findings from multiple studies (level II, III or IV) | |||
|- | |||
|B | |||
|Level II, III or IV evidence with generally consistent findings | |||
|- | |||
|C | |||
|Level II, III or IV evidence with inconsistent findings | |||
|- | |||
|D | |||
|Little or no systematic empirical evidence | |||
|} | |||
=== Diet === | |||
'''Dietary Modifications (Level III; Grade B)''' | |||
* Decrease [[carbohydrate]] intake | |||
** Avoid simple [[Sugar|sugars]] like soda, candy sweets, and cookies | |||
* [[Fluid]] restriction | |||
** Wait at least 30 minutes after a meal before drinking | |||
* Increase [[protein]] intake | |||
* Increase [[fat]] intake | |||
* Increase fiber intake | |||
* [[Dairy]] and [[dairy]] product restriction | |||
* Shorter meals | |||
* Eat slowly | |||
* [[Mastication|Chew]] properly | |||
* Lying [[supine]] for 30 minutes after a meal | |||
* [[Glycemic index]] education of foods is important | |||
== | '''Dietary Supplements (Level III; Grade C)''' | ||
The following work similarly to each other. These supplements increase [[viscosity]] which in turn decreases [[Stomach|gastric]] emptying and causes a delay in [[glucose]] absorption. | |||
* Delay [[glucose]] absorption: | |||
** [[Pectin]] | |||
*** 15 grams of [[Pectin]] is effective | |||
** [[Guar gum]] | |||
*** 15 grams of [[Guar gum]] is effective | |||
** [[Glucomannan]] | |||
*** [[Glucomannan]] improves [[glucose]] tolerance but isn't as effective | |||
* The increased fiber in the supplements leads to [[gas]] and [[bloating]]. This decreases tolerability and in turn reduces [[Compliance (medicine)|compliance]]. | |||
===='''Dietary Foods''' ==== | |||
The following is a table that illustrates the types of food to take and avoid in the case of [[Gastric dumping syndrome|dumping syndrome]]. | |||
{| class="wikitable" style="margin: 1em auto 1em auto" | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Breads, Cereals, Rice and Pasta''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods To Choose''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |''' Foods to Avoid''' | |||
|- | |||
| | |||
* 6-11 servings each day | |||
* One serving equals: 1 slice bread, 1 cup ready-to-eat cereal | |||
** 1/2 cup cooked cereal, rice, or pasta | |||
| | |||
* Breads, bagels, rolls, unsweetened cereals, pasta, potatoes, rice, crackers, and soup (only if taken one hour after [[solid]] foods at medium temperature). | |||
| | |||
* Sweet rolls and doughnuts | |||
* Sweetened cereals | |||
* Pancakes and waffles with syrup | |||
* Soup (taken with solid foods) | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Fruits''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Choose''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods To Avoid''' | |||
|- | |||
| | |||
* 2-4 servings each day | |||
* One serving equals: 1 medium size fresh, 1/2 cup canned, 3/4 cup juice | |||
| | |||
* All fresh fruit | |||
* Drained, unsweetened canned fruit | |||
* Unsweetened frozen fruit | |||
* 100 percent pure juice (taken one hour after meals) | |||
| | |||
* Canned fruits in heavy syrup | |||
* Sweetened frozen fruit | |||
* Sweetened juice (that is, punch or sports drinks) | |||
* Candied fruit | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Milk and Dairy Products''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods To Choose''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Avoid''' | |||
|- | |||
| | |||
* Limit to 2 servings each day | |||
* One serving equals: 1 cup milk or yogurt | |||
| | |||
* Plain or unsweetened yogurt | |||
* Skim, 2 percent, or whole milk (taken one hour after meals) | |||
| | |||
* Milkshakes and chocolate milk | |||
* Sweetened yogurt | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Meats, Poultry, Fish, Dry Beans, Peas, Eggs and Cheese''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Choose''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Avoid''' | |||
|- | |||
| | |||
* 2-3 servings or a total of six ounces daily | |||
** One serving equals: 2-3 ounces cooked meat, chicken, or fish (about the size of a deck of cards) | |||
** or 1/2 to 3/4 cup cottage cheese or tuna fish | |||
** or one egg, 1/2 cup cooked beans, two tablespoons peanut butter, or one ounce of cheese. | |||
* Choose leaner cuts of beef and meat and limit the amount of high-fat items like eggs and cheese. | |||
| | |||
* All meat, fish, poultry, peanut butter, cheese, eggs, and dried beans or legumes | |||
| | |||
* Any not tolerated | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Vegetables''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Choose''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Avoid''' | |||
|- | |||
| | |||
* 3-5 servings each day | |||
* One serving equals: 1 cup raw, 1/2 cup cooked or chopped. | |||
| | |||
* All vegetables | |||
| | |||
* Any not tolerated | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Fats, Condiments and Beverages''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Choose''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Avoid''' | |||
|- | |||
| | |||
| | |||
* All butter, margarine, cream, oil, and salad dressings | |||
* Salt, herbs, spices, and condiments | |||
* Any sugar-free beverage (coffee, tea, diet soda, etc., taken one hour after solids) | |||
| | |||
* Sweet pickles or relish | |||
* Sweetened drinks (regular lemonade, soda) | |||
* Any others not tolerated | |||
|- | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Snacks, Sweets, and Desserts''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Choose''' | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |'''Foods to Avoid''' | |||
|- | |||
| | |||
| | |||
* Sugar-free gelatin | |||
* Sugar-free pudding | |||
* Sugar-free candy | |||
* Sugar substitutes | |||
| | |||
* Sugar | |||
* Candy and chocolate | |||
* Cakes and cookies | |||
* Ice cream and sherbet | |||
* Honey, syrup, and jelly | |||
* Sugar alcohols such as [[sorbitol]], [[xylitol]], and [[mannitol]] | |||
|} | |||
===Drug Therapy=== | |||
Although there are no [[Food and Drug Administration|FDA]] approved [[Medication|medications]] specific for [[Gastric dumping syndrome|dumping syndrome]] the following [[Pharmacology|pharmacological]] interventions are used off-label: | |||
* [[Acarbose]] (Glucobay, Precose, Prandase) | |||
* [[Somatostatin]] analogues such as [[Octreotide]] (Sandostatin) | |||
{| class="wikitable" | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + | | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Acarbose (Level III; Grade B) | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Octreotide (Level II; Grade A) | |||
|- | |||
| align="center" style="background:#DCDCDC;" + |Use | |||
|Late [[Gastric dumping syndrome|dumping syndrome]] | |||
|Early and Late [[Gastric dumping syndrome|dumping syndrome]] | |||
|- | |||
| align="center" style="background:#DCDCDC;" + |Mechanism of Action | |||
|Inhibits [[carbohydrate]] absorption | |||
|Strong inhibitor of the gut [[Hormone|hormones]] (especially [[insulin]]) | |||
|- | |||
| align="center" style="background:#DCDCDC;" + |Dose | |||
| | |||
* Rebound [[hypoglycemia]]: 25 mg before breakfast, lunch and dinner | |||
* Initiate effect: 50 mg daily (QD) | |||
* For complete [[resolution]] of [[Symptom|symptoms]]: 50/100 mg three times daily (TID). Especially beneficial in [[Diabetes mellitus|diabetics]] with [[Gastric dumping syndrome|dumping syndrome]] | |||
| | |||
* Initiate effect: 25-50 μg S.C two-three times daily (BID or TID) | |||
* Maximum effect: 100-200 μg S.C two-three times daily (BID or TID) | |||
* Long-acting (New) I.M once monthly | |||
|- | |||
| align="center" style="background:#DCDCDC;" + |Effect | |||
| | |||
* Decrease [[postprandial]] [[hyperglycemia]] | |||
* Decrease [[postprandial]] [[hypotension]] | |||
* Decrease [[Stomach|gastric]] emptying | |||
* Increase [[insulin]] secretion | |||
| | |||
* Decrease [[Symptom|symptoms]] | |||
* Improves Sigstad's score | |||
* Inhibits vasodilation | |||
* Decrease [[insulin]] levels | |||
* Decrease [[Stomach|gastric]] emptying | |||
* Inhibits [[splanchnic]] [[vasoconstriction]] | |||
|- | |||
| align="center" style="background:#DCDCDC;" + |Additional information | |||
| | |||
* Limited to [[diarrhea]] severity | |||
* [[Therapy]] role not yet clarified | |||
| | |||
* Good for long-term [[refractory]] [[Gastric dumping syndrome|dumping syndrome]] | |||
* [[Adverse effect (medicine)|Side effects]] are the reason for stopping long-term therapy. Treat this by giving an extra [[dose]] before sleeping or a [[Pancreas|pancreatic]] [[Enzyme replacement therapy|enzyme replacement]]. | |||
* Short-acting improves symptoms | |||
* New long-acting release is effective, increases [[weight]] and improves the [[quality of life]] | |||
* Safe | |||
* Last resort drug | |||
|} | |||
<br> | |||
'''Somatostatin analogues''' | |||
* [[Pasireotide]] has a higher receptor [[Chemical affinity|affinity]] than [[octreotide]] and is more effective but it does not reduce [[Gastric dumping syndrome|dumping syndrome]] [[Symptom|symptoms]] as well as [[octreotide]]. | |||
* Even though [[pasireotide]] has been safe and effective no results of its clinical trials have been published to date.<br> | |||
=== Drug summary === | |||
* | {| class="wikitable" | ||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Drug | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Dose | |||
! align="center" style="background:#4479BA; color: #FFFFFF;" + |Effect | |||
|- | |||
|[[Tolbutamide]]<ref name="pmid5346670">{{cite journal |vauthors=Sigstad H |title=Effect of tolbutamide on the dumping syndrome |journal=Scand. J. Gastroenterol. |volume=4 |issue=3 |pages=227–31 |year=1969 |pmid=5346670 |doi= |url=}}</ref> | |||
|0.25-0.75 g, TID | |||
|Subjective improvement | |||
|- | |||
|[[Propranolol]]<ref name="pmid3369789">{{cite journal |vauthors=Niv Y |title=The early dumping syndrome and propranolol |journal=Ann. Intern. Med. |volume=108 |issue=6 |pages=910–1 |year=1988 |pmid=3369789 |doi= |url=}}</ref> | |||
|10 mg, QID | |||
|Reduced early dumping | |||
|- | |||
|[[Cyproheptadine hydrochloride|Cyproheptadine]]<ref name="pmid1183731">{{cite journal |vauthors=Leichter SB, Permutt MA |title=Effect of adrenergic agents on postgastrectomy hypoglycemia |journal=Diabetes |volume=24 |issue=11 |pages=1005–10 |year=1975 |pmid=1183731 |doi= |url=}}</ref> | |||
|4-8 mg, TID | |||
|Preventing vasomotor [[Symptom|symptoms]] | |||
|- | |||
|[[Methysergide|Methysergide maleate]]<ref name="pmid5439191">{{cite journal |vauthors=Bernard PF, Baschet C, Le Henand F, Bouderlique JR, Lortat-Jacob JL |title=[Treatment of 65 cases of dumping syndrome with methysergide in recently gastrectomized patients] |language=French |journal=Presse Med |volume=78 |issue=12 |pages=549–50 |year=1970 |pmid=5439191 |doi= |url=}}</ref> | |||
|4-8 mg, TID | |||
|Reduced vasomotor [[Symptom|symptoms]] | |||
|- | |||
|[[Verapamil]]<ref name="pmid2309689">{{cite journal |vauthors=Tabibian N |title=Successful treatment of refractory post-vagotomy syndrome with verapamil (Calan SR) |journal=Am. J. Gastroenterol. |volume=85 |issue=3 |pages=328–9 |year=1990 |pmid=2309689 |doi= |url=}}</ref> | |||
|120-240 mg, QD | |||
|Reduced vasomotor [[Symptom|symptoms]] | |||
|- | |||
|[[Acarbose]]<ref name="pmid9918426">{{cite journal |vauthors=Hasegawa T, Yoneda M, Nakamura K, Ohnishi K, Harada H, Kyouda T, Yoshida Y, Makino I |title=Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome |journal=J. Gastroenterol. Hepatol. |volume=13 |issue=12 |pages=1201–6 |year=1998 |pmid=9918426 |doi= |url=}}</ref> | |||
|50-100 mg, TID | |||
|Reduced late dumping | |||
|- | |||
|[[Octreotide]]<ref name="pmid9200302">{{cite journal |vauthors=Vecht J, Masclee AA, Lamers CB |title=The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment |journal=Scand. J. Gastroenterol. Suppl. |volume=223 |issue= |pages=21–7 |year=1997 |pmid=9200302 |doi= |url=}}</ref> | |||
|25-100 mcg, TID | |||
|Reduced vasomotor [[Symptom|symptoms]] | |||
|- | |||
|[[Pantoprazole]] (PPI)<ref name="pmid20012198">{{cite journal |vauthors=Sanaka M, Yamamoto T, Kuyama Y |title=Effects of proton pump inhibitors on gastric emptying: a systematic review |journal=Dig. Dis. Sci. |volume=55 |issue=9 |pages=2431–40 |year=2010 |pmid=20012198 |doi=10.1007/s10620-009-1076-x |url=}}</ref> | |||
| | |||
|Subjective improvement | |||
|- | |||
|[[Cholestyramine]]<ref name="pmid24199211">{{cite journal |vauthors=Barkun AN, Love J, Gould M, Pluta H, Steinhart H |title=Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment |journal=Can. J. Gastroenterol. |volume=27 |issue=11 |pages=653–9 |year=2013 |pmid=24199211 |pmc=3816948 |doi= |url=}}</ref> | |||
| | |||
|Subjective improvement | |||
|- | |||
|[[Diazoxide]]<ref name="pmid26901345">{{cite journal |vauthors=Vilarrasa N, Goday A, Rubio MA, Caixàs A, Pellitero S, Ciudin A, Calañas A, Botella JI, Bretón I, Morales MJ, Díaz-Fernández MJ, García-Luna PP, Lecube A |title=Hyperinsulinemic Hypoglycemia after Bariatric Surgery: Diagnosis and Management Experience from a Spanish Multicenter Registry |journal=Obes Facts |volume=9 |issue=1 |pages=41–51 |year=2016 |pmid=26901345 |pmc=5644871 |doi=10.1159/000442764 |url=}}</ref> | |||
|75-260 mg, QD | |||
|Subjective improvement | |||
|- | |||
|[[Nifedipine]]<ref name="pmid19625246">{{cite journal |vauthors=Guseva N, Phillips D, Mordes JP |title=Successful treatment of persistent hyperinsulinemic hypoglycemia with nifedipine in an adult patient |journal=Endocr Pract |volume=16 |issue=1 |pages=107–11 |year=2010 |pmid=19625246 |pmc=3979460 |doi=10.4158/EP09110.CRR |url=}}</ref> | |||
|30 mg, QD | |||
|Reduced [[Hypoglycemia|hypoglycemic]] [[Symptom|symptoms]] | |||
|- | |||
|Exendin 9-39<ref name="pmid24315990">{{cite journal |vauthors=Salehi M, Gastaldelli A, D'Alessio DA |title=Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass |journal=Gastroenterology |volume=146 |issue=3 |pages=669–680.e2 |year=2014 |pmid=24315990 |pmc=3943944 |doi=10.1053/j.gastro.2013.11.044 |url=}}</ref> | |||
|7500 pmol/kg prime | |||
|Reduced [[Hypoglycemia|hypoglycemic]] [[Symptom|symptoms]] | |||
|} | |||
<br>'''Effects of surgery on medications''' | |||
* After RYGB [[surgery]], [[bioavailability]] is decreased in [[:Category:Drugs|drugs]] such as:<ref name="pmid21538168">{{cite journal |vauthors=Padwal R, Klarenbach S, Wiebe N, Hazel M, Birch D, Karmali S, Sharma AM, Manns B, Tonelli M |title=Bariatric surgery: a systematic review of the clinical and economic evidence |journal=J Gen Intern Med |volume=26 |issue=10 |pages=1183–94 |year=2011 |pmid=21538168 |pmc=3181300 |doi=10.1007/s11606-011-1721-x |url=}}</ref><ref name="pmid22095812">{{cite journal |vauthors=Smith A, Henriksen B, Cohen A |title=Pharmacokinetic considerations in Roux-en-Y gastric bypass patients |journal=Am J Health Syst Pharm |volume=68 |issue=23 |pages=2241–7 |year=2011 |pmid=22095812 |doi=10.2146/ajhp100630 |url=}}</ref><ref name="pmid19493300">{{cite journal |vauthors=Padwal R, Brocks D, Sharma AM |title=A systematic review of drug absorption following bariatric surgery and its theoretical implications |journal=Obes Rev |volume=11 |issue=1 |pages=41–50 |year=2010 |pmid=19493300 |doi=10.1111/j.1467-789X.2009.00614.x |url=}}</ref><ref name="pmid22998066">{{cite journal |vauthors=Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS |title=The effects of gastric bypass surgery on drug absorption and pharmacokinetics |journal=Expert Opin Drug Metab Toxicol |volume=8 |issue=12 |pages=1505–19 |year=2012 |pmid=22998066 |doi=10.1517/17425255.2012.722757 |url=}}</ref><ref name="pmid23835364">{{cite journal |vauthors=Titus R, Kastenmeier A, Otterson MF |title=Consequences of gastrointestinal surgery on drug absorption |journal=Nutr Clin Pract |volume=28 |issue=4 |pages=429–36 |year=2013 |pmid=23835364 |doi=10.1177/0884533613490740 |url=}}</ref> | |||
** [[Amoxicillin]] | |||
** [[Azithromycin]] | |||
** [[Cyclosporine|Cyclosporine A]] | |||
** [[Levothyroxine]] | |||
** [[Nitrofurantoin]] | |||
** [[Mycophenolate sodium|Mycophenolic acid]] | |||
** [[Phenytoin]], [[phenobarbital]] | |||
** [[Sirolimus]] | |||
** T[[tacrolimus|acrolimus]] | |||
** [[Tamoxifen]] | |||
* Surgeries that decrease the [[stomach]] size may increase [[toxicity]] of: | |||
** [[Non-steroidal anti-inflammatory drug|Nonsteroidal anti-inflammatory drugs]] | |||
** [[Salicylic acid|Salicylates]] | |||
** Oral [[Bisphosphonate|bisphosphonates]] | |||
** Oral [[iron]] | |||
* Any procedure that leads to dumping syndrome will: | |||
** Increases [[Gastrointestinal tract|gut]] transit time | |||
** Decease [[:Category:Drugs|drug]] [[absorption]] | |||
<br> | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | {{WH}} | ||
{{WS}} | {{WS}} |
Latest revision as of 19:38, 19 December 2017
Gastric dumping syndrome Microchapters |
Differentiating Gastric dumping syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Gastric dumping syndrome medical therapy On the Web |
American Roentgen Ray Society Images of Gastric dumping syndrome medical therapy |
Risk calculators and risk factors for Gastric dumping syndrome medical therapy |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Umar Ahmad, M.D.[2]
Overview
The main therapy for the management of dumping syndrome includes diet and pharmacological intervention.
Approach to Management
The following algorithm demonstrates the course of action in the approach of the management of dumping syndrome:
Gastric or Esophageal Surgery | |||||||||||||||||||||||||||||||||||||||||||||
Early dumping symptoms | Late dumping symptoms | ||||||||||||||||||||||||||||||||||||||||||||
Diagnosis | Measure Glucose | ||||||||||||||||||||||||||||||||||||||||||||
Confirm diagnosis with OGTT | |||||||||||||||||||||||||||||||||||||||||||||
Dietary modifications | Dietary supplements | ||||||||||||||||||||||||||||||||||||||||||||
Acarbose | |||||||||||||||||||||||||||||||||||||||||||||
Treatment | Somatostatin analogues | ||||||||||||||||||||||||||||||||||||||||||||
Treatment refractory dumping syndrome | |||||||||||||||||||||||||||||||||||||||||||||
Surgical re-intervention or Continuous enteral feeding | |||||||||||||||||||||||||||||||||||||||||||||
Medical Therapy
Medical therapy for dumping syndrome includes diet and drug therapy.[1]
Level of evidence | Type of evidence |
---|---|
I | Evidence from meta-analysis of multiple, well-designed, controlled studies (randomized trials with low false-positive and low false-negative errors) |
II | Evidence from at least 1 well-designed, quasi-experimental study (randomized trials with high false-positive and high false-negative errors) |
III | Evidence from well-designed, quasi-experimental studies (nonrandomized, controlled, single-group, pre–post, cohort and time or matched case–control series) |
IV | Evidence from well-designed, non-experimental studies (comparative and correlational descriptive and case studies) |
V | Evidence from case reports |
Grade of recommendation | Level of evidence |
A | Level I evidence or consistent findings from multiple studies (level II, III or IV) |
B | Level II, III or IV evidence with generally consistent findings |
C | Level II, III or IV evidence with inconsistent findings |
D | Little or no systematic empirical evidence |
Diet
Dietary Modifications (Level III; Grade B)
- Decrease carbohydrate intake
- Avoid simple sugars like soda, candy sweets, and cookies
- Fluid restriction
- Wait at least 30 minutes after a meal before drinking
- Increase protein intake
- Increase fat intake
- Increase fiber intake
- Dairy and dairy product restriction
- Shorter meals
- Eat slowly
- Chew properly
- Lying supine for 30 minutes after a meal
- Glycemic index education of foods is important
Dietary Supplements (Level III; Grade C)
The following work similarly to each other. These supplements increase viscosity which in turn decreases gastric emptying and causes a delay in glucose absorption.
- Delay glucose absorption:
- Pectin
- 15 grams of Pectin is effective
- Guar gum
- 15 grams of Guar gum is effective
- Glucomannan
- Glucomannan improves glucose tolerance but isn't as effective
- Pectin
- The increased fiber in the supplements leads to gas and bloating. This decreases tolerability and in turn reduces compliance.
Dietary Foods
The following is a table that illustrates the types of food to take and avoid in the case of dumping syndrome.
Breads, Cereals, Rice and Pasta | Foods To Choose | Foods to Avoid |
---|---|---|
|
|
|
Fruits | Foods to Choose | Foods To Avoid |
|
|
|
Milk and Dairy Products | Foods To Choose | Foods to Avoid |
|
|
|
Meats, Poultry, Fish, Dry Beans, Peas, Eggs and Cheese | Foods to Choose | Foods to Avoid |
|
|
|
Vegetables | Foods to Choose | Foods to Avoid |
|
|
|
Fats, Condiments and Beverages | Foods to Choose | Foods to Avoid |
|
| |
Snacks, Sweets, and Desserts | Foods to Choose | Foods to Avoid |
|
Drug Therapy
Although there are no FDA approved medications specific for dumping syndrome the following pharmacological interventions are used off-label:
- Acarbose (Glucobay, Precose, Prandase)
- Somatostatin analogues such as Octreotide (Sandostatin)
Acarbose (Level III; Grade B) | Octreotide (Level II; Grade A) | |
---|---|---|
Use | Late dumping syndrome | Early and Late dumping syndrome |
Mechanism of Action | Inhibits carbohydrate absorption | Strong inhibitor of the gut hormones (especially insulin) |
Dose |
|
|
Effect |
|
|
Additional information |
|
Somatostatin analogues
- Pasireotide has a higher receptor affinity than octreotide and is more effective but it does not reduce dumping syndrome symptoms as well as octreotide.
- Even though pasireotide has been safe and effective no results of its clinical trials have been published to date.
Drug summary
Drug | Dose | Effect |
---|---|---|
Tolbutamide[2] | 0.25-0.75 g, TID | Subjective improvement |
Propranolol[3] | 10 mg, QID | Reduced early dumping |
Cyproheptadine[4] | 4-8 mg, TID | Preventing vasomotor symptoms |
Methysergide maleate[5] | 4-8 mg, TID | Reduced vasomotor symptoms |
Verapamil[6] | 120-240 mg, QD | Reduced vasomotor symptoms |
Acarbose[7] | 50-100 mg, TID | Reduced late dumping |
Octreotide[8] | 25-100 mcg, TID | Reduced vasomotor symptoms |
Pantoprazole (PPI)[9] | Subjective improvement | |
Cholestyramine[10] | Subjective improvement | |
Diazoxide[11] | 75-260 mg, QD | Subjective improvement |
Nifedipine[12] | 30 mg, QD | Reduced hypoglycemic symptoms |
Exendin 9-39[13] | 7500 pmol/kg prime | Reduced hypoglycemic symptoms |
Effects of surgery on medications
- After RYGB surgery, bioavailability is decreased in drugs such as:[14][15][16][17][18]
- Surgeries that decrease the stomach size may increase toxicity of:
- Any procedure that leads to dumping syndrome will:
- Increases gut transit time
- Decease drug absorption
References
- ↑ Ukleja A (2005). "Dumping syndrome: pathophysiology and treatment". Nutr Clin Pract. 20 (5): 517–25. doi:10.1177/0115426505020005517. PMID 16207692.
- ↑ Sigstad H (1969). "Effect of tolbutamide on the dumping syndrome". Scand. J. Gastroenterol. 4 (3): 227–31. PMID 5346670.
- ↑ Niv Y (1988). "The early dumping syndrome and propranolol". Ann. Intern. Med. 108 (6): 910–1. PMID 3369789.
- ↑ Leichter SB, Permutt MA (1975). "Effect of adrenergic agents on postgastrectomy hypoglycemia". Diabetes. 24 (11): 1005–10. PMID 1183731.
- ↑ Bernard PF, Baschet C, Le Henand F, Bouderlique JR, Lortat-Jacob JL (1970). "[Treatment of 65 cases of dumping syndrome with methysergide in recently gastrectomized patients]". Presse Med (in French). 78 (12): 549–50. PMID 5439191.
- ↑ Tabibian N (1990). "Successful treatment of refractory post-vagotomy syndrome with verapamil (Calan SR)". Am. J. Gastroenterol. 85 (3): 328–9. PMID 2309689.
- ↑ Hasegawa T, Yoneda M, Nakamura K, Ohnishi K, Harada H, Kyouda T, Yoshida Y, Makino I (1998). "Long-term effect of alpha-glucosidase inhibitor on late dumping syndrome". J. Gastroenterol. Hepatol. 13 (12): 1201–6. PMID 9918426.
- ↑ Vecht J, Masclee AA, Lamers CB (1997). "The dumping syndrome. Current insights into pathophysiology, diagnosis and treatment". Scand. J. Gastroenterol. Suppl. 223: 21–7. PMID 9200302.
- ↑ Sanaka M, Yamamoto T, Kuyama Y (2010). "Effects of proton pump inhibitors on gastric emptying: a systematic review". Dig. Dis. Sci. 55 (9): 2431–40. doi:10.1007/s10620-009-1076-x. PMID 20012198.
- ↑ Barkun AN, Love J, Gould M, Pluta H, Steinhart H (2013). "Bile acid malabsorption in chronic diarrhea: pathophysiology and treatment". Can. J. Gastroenterol. 27 (11): 653–9. PMC 3816948. PMID 24199211.
- ↑ Vilarrasa N, Goday A, Rubio MA, Caixàs A, Pellitero S, Ciudin A, Calañas A, Botella JI, Bretón I, Morales MJ, Díaz-Fernández MJ, García-Luna PP, Lecube A (2016). "Hyperinsulinemic Hypoglycemia after Bariatric Surgery: Diagnosis and Management Experience from a Spanish Multicenter Registry". Obes Facts. 9 (1): 41–51. doi:10.1159/000442764. PMC 5644871. PMID 26901345.
- ↑ Guseva N, Phillips D, Mordes JP (2010). "Successful treatment of persistent hyperinsulinemic hypoglycemia with nifedipine in an adult patient". Endocr Pract. 16 (1): 107–11. doi:10.4158/EP09110.CRR. PMC 3979460. PMID 19625246.
- ↑ Salehi M, Gastaldelli A, D'Alessio DA (2014). "Blockade of glucagon-like peptide 1 receptor corrects postprandial hypoglycemia after gastric bypass". Gastroenterology. 146 (3): 669–680.e2. doi:10.1053/j.gastro.2013.11.044. PMC 3943944. PMID 24315990.
- ↑ Padwal R, Klarenbach S, Wiebe N, Hazel M, Birch D, Karmali S, Sharma AM, Manns B, Tonelli M (2011). "Bariatric surgery: a systematic review of the clinical and economic evidence". J Gen Intern Med. 26 (10): 1183–94. doi:10.1007/s11606-011-1721-x. PMC 3181300. PMID 21538168.
- ↑ Smith A, Henriksen B, Cohen A (2011). "Pharmacokinetic considerations in Roux-en-Y gastric bypass patients". Am J Health Syst Pharm. 68 (23): 2241–7. doi:10.2146/ajhp100630. PMID 22095812.
- ↑ Padwal R, Brocks D, Sharma AM (2010). "A systematic review of drug absorption following bariatric surgery and its theoretical implications". Obes Rev. 11 (1): 41–50. doi:10.1111/j.1467-789X.2009.00614.x. PMID 19493300.
- ↑ Brocks DR, Ben-Eltriki M, Gabr RQ, Padwal RS (2012). "The effects of gastric bypass surgery on drug absorption and pharmacokinetics". Expert Opin Drug Metab Toxicol. 8 (12): 1505–19. doi:10.1517/17425255.2012.722757. PMID 22998066.
- ↑ Titus R, Kastenmeier A, Otterson MF (2013). "Consequences of gastrointestinal surgery on drug absorption". Nutr Clin Pract. 28 (4): 429–36. doi:10.1177/0884533613490740. PMID 23835364.